Claris Lifesciences has completed the sale of its global generic injectables business to Baxter International Inc. (USA) for an enterprise value of $625 million.
The company further clarified that it will discuss; with its advisors; and identify the most efficient method of transferring a significant majority of the net proceeds to its shareholder, the company expects to communicate the process before October 15, 2017.
Claris Lifesciences is engaged in manufacturing of drugs and pharmaceutical products. The Company manufactures and markets products across multiple delivery systems, markets and therapeutic segments, including anesthesia and analgesics, blood products, anti-invective's, critical care, and nephrology.
